Neil Warma

Neil Warma has been a successful healthcare entrepreneur for over 25 years, having managed and advised numerous biotechnology and pharmaceutical companies across the globe. Mr. Warma became interim CEO of ProMIS Neurosciences in January 2024. Prior to that he was CEO, Representative Director and Board Member of Genexine, Inc. (095700.KQ) a public, global biopharmaceutical company based in Seoul, South Korea, where he led the company’s restructuring and commercialization of its first products.

Previously, Mr. Warma was the US General Manager of I-Mab Biopharma U.S. (Nasdaq: IMAB), a publicly traded global biopharmaceutical company focused on oncology, with offices in Shanghai, Hong Kong, San Diego and Gaithersburg, where he was responsible for the expansion of global operations and a key driver in I-Mab’s U.S. IPO.

Prior to that, Mr. Warma was President and CEO of Opexa Therapeutics, Inc. (Nasdaq: OPXA), a publicly traded biopharmaceutical company developing novel cellular therapies for autoimmune diseases. Prior to Opexa, he was CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics for cardiovascular disease and transplantation.

Mr. Warma spent several years in key management roles at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland in Global Marketing and as Head of International Pharma Policy. He was also President and Co-Founder of MedExact, a health-technology company dedicated to providing an interface between physicians and pharmaceutical companies, which he later sold.

Mr. Warma currently serves on the Board of Directors of the Biotechnology Innovation Organization (BIO). Mr. Warma obtained an honors Bachelor of Science degree specializing in Neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto.